These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37500340)

  • 1. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
    Plimack ER; Powles T; Stus V; Gafanov R; Nosov D; Waddell T; Alekseev B; Pouliot F; Melichar B; Soulières D; Borchiellini D; McDermott RS; Vynnychenko I; Chang YH; Tamada S; Atkins MB; Li C; Perini R; Molife LR; Bedke J; Rini BI
    Eur Urol; 2023 Nov; 84(5):449-454. PubMed ID: 37500340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
    Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
    Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
    Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
    Grünwald V; Powles T; Kopyltsov E; Kozlov V; Alonso-Gordoa T; Eto M; Hutson T; Motzer R; Winquist E; Maroto P; Keam B; Procopio G; Wong S; Melichar B; Rolland F; Oya M; Rodriguez-Lopez K; Saito K; McKenzie J; Porta C
    Eur Urol Oncol; 2023 Aug; 6(4):437-446. PubMed ID: 36720658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
    Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
    Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
    Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
    Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
    Lara PN; Villanueva L; Ibanez C; Erman M; Lee JL; Heinrich D; Lipatov ON; Gedye C; Gokmen E; Acevedo A; Semenov A; Park SH; Gafanov RA; Kose F; Jones M; Du X; Munteanu M; Perini R; Choueiri TK; Motzer RJ
    BMC Cancer; 2024 Jul; 23(Suppl 1):1253. PubMed ID: 39054430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
    ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
    Capitanio U; Fallara G; Raggi D; Nocera L; Larcher A; Belladelli F; Rowe I; Briganti A; Salonia A; Karakiewicz P; Montorsi F; Martini A; Necchi A
    Curr Probl Cancer; 2022 Aug; 46(4):100875. PubMed ID: 35679628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
    N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
    Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG
    Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
    Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
    ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
    Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
    Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
    Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
    Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.